Heart Implants (Global Market)

Cardiac Implants (Russian Market)

Main article: Heart implants (Russian market)

2024: Global Heart Implant Market Size Reaches $16.31 Billion for the Year

In 2024, the global market for heart implants amounted to $16.31 billion. For comparison, a year earlier, expenses in this area were estimated at $14.93 billion. Thus, an increase of 9.2% was recorded. This is stated in a study by MarketsandMarkets, the results of which Zdrav.Expert got acquainted with at the end of June 2025.

Analysts take into account the supply of such products as artificial heart valves (axisymmetric valves, three-leaf valves, etc.), occluders, annuloplasty rings, etc. The demand for such products is growing against the background of an increase in the prevalence of cardiovascular diseases (CVD). According to the World Health Organization ( WHO ), it is CVDs that are the main cause of disability and premature death in the European Region: they account for more than 42.5% of all deaths. Globally, CVDs are estimated to kill approximately 17.9 million people each year, representing 32% of all deaths worldwide. About 85% of these deaths are caused by myocardial infarction and stroke.

𝓲

Фото: Freepik

The study says that in 2024 the most popular were products that are used in transcatheter operations on valves. The increasing prevalence of valvular heart pathologies, especially in an aging population, is fueling demand for these devices. The fact is that as the number of older people increases, conditions such as aortic stenosis become more common. Transcatheter aortic valve implantation (TAVI) allows aortic valve implantation without open heart surgery - through minimally invasive intervention. The valve is implanted through a punctured femoral artery (the most commonly used technique) using a dedicated catheter and delivery system. In general, the authors of the study note, the combination of such factors as an aging population, technological innovations and an increasing demand for minimally invasive procedures leads to an increase in the demand for transcatheter heart valves.

Geographically, North America leads the global heart implant market. The review said the U.S. and Canada have developed health infrastructure, including large hospital systems and extensive networks of health care providers. Meanwhile, aging populations in the region, sedentary lifestyles, low levels of physical activity and unhealthy diets contribute to an increase in the prevalence of cardiovascular disease. As a result, the demand for heart implants increases.

The industry is positively impacted by technological advances fueled by significant investment in research activities to develop and implement advanced medical systems. Globally, significant players are named:

• Edwards Lifesciences;
• Boston Scientific;
• Medtronic;
• Philips;
• Merit Medical Systems;
• Abbott;
• Terumo;
• Teleflex;
• Integer Holdings;
• Lepu Medical Technology;
• TTK;
• Artivion;
• Venus Medtech;
• Cook;
• SMT;
• Meril Lifesciences Pvt.Ltd;
• W.L Gore & Associates;
• Cordis;
• Foldax;
• Micro Interventional Devices;
• Cardiac Dimensions;
• HighLife Medical;
• Mitralign;
• Braile Biomedica;
• JenaValve;
• Corcym;
• Xeltis;
• Innovheart SRL.

MarketsandMarkets analysts believe that in the future, the CAGR in the market under consideration will be approximately 9.5%. Thus, by 2029, costs may increase to $25.69 billion.^[1]

2023: Biodegradable implant introduced to monitor heart function

On July 5, 2021, American researchers from Northwestern University and George Washington University announced the development of a new implantable device for monitoring heart activity. Read more here.

2018: Artificial heart valves sales reach $9.28 billion

In early June 2019, the analytical company MarketsandMarkets presented a research report, according to which the global market for devices used to replace affected heart valves will reach $15 billion by 2023, while back in 2018 it was $9.28 billion. The largest manufacturers of such implants are named Edwards Lifesciences and Medtronic.

To blame these companies, analysts distinguish several more major players: Abbott Laboratories (USA), Boston Scientific ( USA) and LivaNova (UK). Merging and entering into partnership agreements became the main strategy of these companies, and by 2019 such large firms as Micro Interventional Devices (USA), Braile Biomédica (Brazil) and CryoLife (USA) joined them.

The largest manufacturers of artificial heart valves are Edwards Lifesciences and Medtronic

Edwards Lifesciences has taken a leading position in the global market due to its diverse range of valve replacement products. The company is constantly expanding: for example, in December 2017, it acquired Harpoon Medical (USA) for $100 million, which supplemented the Edwards portfolio with a unique technology for implanting a mitral valve without cardiac arrest.

Medtronic took the second position in the artificial valve manufacturers market. The company offers a wide range of products for traditional and transcatheter implantation of heart valves. To maintain a leading market position and increase the customer base, the company focuses on developing new devices, entering into partnership agreements and expanding production. For example, the company has partnered with the World Stroke Organization (WSO, Switzerland). As part of this partnership, the two organizations inform the population about the problem of stroke and its consequences, as well as ensure the effective management of post-stroke patients.^[2]

Notes